Top Markets
Coin of the day
Alpha Cognition Inc Alpha Cognition Inc

Alpha Cognition Inc

ACOG
Classifica tra le azioni #19830
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Prezzo delle azioni
$9.61
Capitalizzazione di mercato
$149.33M
Variazione (1 giorno)
-1.39%
Variazione (1 anno)
24.38%
Paese
US
Scambia Alpha Cognition Inc (ACOG)

Categoria

Rapporto P/B per Alpha Cognition Inc (ACOG)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Alpha Cognition Inc, il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Alpha Cognition Inc da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH